TME Pharma N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALTME.PA research report →
About the company
TME Pharma N. V. , a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer.
- CEO
- Diede van den Ouden
- IPO
- 2016
- Employees
- 12
- HQ
- Berlin, DE
Price Chart
- Market Cap
- $6.47M
- P/E
- -1.97
- P/S
- 0.00
- P/B
- -4.10
- EV/EBITDA
- -2.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 305.72%
- ROIC
- -270.01%
- Revenue
- $0 · -100.00%
- Net Income
- $-3,285,000 · 42.59%
- EPS
- $-0.03 · 83.38%
- Op Income
- $-2,908,000
- FCF YoY
- 26.52%
- 52W High
- $0.15
- 52W Low
- $0.05
- 50D MA
- $0.08
- 200D MA
- $0.08
- Beta
- 0.64
- Avg Volume
- 220.98K
Get TickerSpark's AI analysis on ALTME.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALTME.PA coverage
Recent articles, reports, and earnings notes.
No research on ALTME.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALTME.PA report →Similar companies
Peers in the same neighborhood.